Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients
Altabás-González, Irene (Complexo Hospitalario Universitario de Vigo)
Pego-Reigosa, José María (Complexo Hospitalario Universitario de Vigo)
Mouriño, Coral (Instituto de Investigación Sanitaria Galicia Sur)
Jiménez, Norman (Instituto de Investigación Sanitaria Galicia Sur)
Hernández-Martín, Andrea (Hospital Universitario de Gran Canaria Dr. Negrín)
Casafont Solé, Ivette (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Font Urguelles, Judit (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Román-Ivorra, José Andrés (Hospital Universitari i Politècnic La Fe (València))
de-la-Rubia-Navarro, Marta (Hospital Universitari i Politècnic La Fe (València))
Galindo-Izquierdo, María (Hospital Universitario 12 de Octubre (Madrid))
Salman-Monte, Tarek Carlos (Parc de Salut MAR de Barcelona)
Narváez, Javier (Institut d'Investigació Biomèdica de Bellvitge)
Vidal-Montal, Paola (Institut d'Investigació Biomèdica de Bellvitge)
García-Villanueva, María Jesús (Hospital Universitario Ramón y Cajal (Madrid))
Garrote-Corral, Sandra (Institut d'Investigació Biomèdica de Bellvitge)
Blázquez-Cañamero, María Ángeles (Hospital Universitario Severo Ochoa)
Marras, Carlos (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Piqueras-García, María (Hospital Universitario Virgen de la Arrixaca (Múrcia))
Martínez-Barrio, Julia (Hospital General Universitario Gregorio Marañón)
Sánchez-Lucas, Marina (Hospital General Universitario Gregorio Marañón)
Cortés Hernández, Josefina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Penzo, Eleonora (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Calvo Alén, Jaime (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
de Dios, Juan Ramón (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Rodríguez, Belén Álvarez (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Vasques-Rocha, Margarida (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Tomero, Eva (Hospital Universitario de la Princesa (Madrid))
Menor-Almagro, Raúl (Hospital Universitario de Jerez (Jerez de la Frontera))
Gandía, Myriam (Hospital Universitario de Jerez (Jerez de la Frontera))
Gómez-Puerta, Jose A (Hospital Clínic i Provincial de Barcelona)
Frade-sosa, Beatriz (Hospital Clínic i Provincial de Barcelona)
Ramos-Giráldez, Consuelo (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Trapero-Pérez, Carmen (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Diez, Elvira (Complejo Asistencial Universitario de León)
Moriano, Clara (Complejo Asistencial Universitario de León)
Muñoz-Jiménez, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Rua Figueroa, Íñigo (Hospital Universitario de Gran Canaria Dr. Negrín)

Date:	2025
Abstract:	Objectives: To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. Methods: A longitudinal retrospective multicenter cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12 months after initiation, and at the last recorded visit. Changes in SLEDAI-2K, the proportion of patients who achieved LLDAS and DORIS 2021, and number of flares were compared between visits. Changes in damage, glucocorticoids use and employment status pre-BLM and post-BLM were also assessed. Results: A total of 324 patients were included with a mean follow-up of 3. 8 (62. 7) years. LLDAS was attained by 45. 8%, 62% and 71% of patients, and DORIS by 24%, 36. 2% and 52. 5% on successive visits, respectively. A total of 27. 2% of patients were in DORIS ≥50% of the visits and 46% in LLDAS-50. Flares and number of flares were significantly lower one year after treatment with BLM and no changes in damage accrual were observed. Mean (6SD) prednisone dose was significantly reduced over time, with 70 (24%) patients discontinuing GC. Conclusion: Our study not only demonstrates belimumab's efficacy in attaining treat-to-target goals in SLE patients, but also confirms its GC-sparing effect, and its prevention of flares and organ damage accrual.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Systemic lupus erythematosus ; Belimumab ; Biologics ; Remission ; DORIS ; LLDAS ; Target ; Spanish ; Cohort ; Effectiveness
Published in:	Rheumatology, Vol. 64 Núm. 1 (January 2025) , p. 276-282, ISSN 1462-0332

DOI: 10.1093/rheumatology/kead696
PMID: 38490245

7 p, 524.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles